AGEX THERAPEUTICS INC (AGE)
US00848H2076 - Common Stock
We assign a fundamental rating of 1 out of 10 to AGE. AGE was compared to 587 industry peers in the Biotechnology industry. AGE has a bad profitability rating. Also its financial health evaluation is rather negative. AGE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
AGE had negative earnings in the past year.
In the past year AGE has reported a negative cash flow from operations.
In the past 5 years AGE always reported negative net income.
In the past 5 years AGE always reported negative operating cash flow.
1.2 Ratios
AGE's Return On Assets of -115.07% is on the low side compared to the rest of the industry. AGE is outperformed by 82.31% of its industry peers.
Looking at the Return On Equity, with a value of -166.86%, AGE is doing worse than 69.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.07% | ||
| ROE | -166.86% | ||
| ROIC | N/A |
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AGE (50.00%) is better than 80.27% of its industry peers.
In the last couple of years the Gross Margin of AGE has declined.
AGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
2. Health
2.1 Basic Checks
AGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGE has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for AGE has been increased compared to 5 years ago.
AGE has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 49.65 indicates that AGE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 49.65, AGE belongs to the best of the industry, outperforming 96.94% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that AGE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, AGE is doing worse than 64.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 49.65 |
ROIC/WACCN/A
WACC9.52%
2.3 Liquidity
AGE has a Current Ratio of 0.36. This is a bad value and indicates that AGE is not financially healthy enough and could expect problems in meeting its short term obligations.
AGE's Current ratio of 0.36 is on the low side compared to the rest of the industry. AGE is outperformed by 96.26% of its industry peers.
AGE has a Quick Ratio of 0.36. This is a bad value and indicates that AGE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.36, AGE is doing worse than 96.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.36 | ||
| Quick Ratio | 0.36 |
3. Growth
3.1 Past
The earnings per share for AGE have decreased strongly by -42.31% in the last year.
The Revenue has grown by 66.67% in the past year. This is a very strong growth!
Measured over the past years, AGE shows a very negative growth in Revenue. The Revenue has been decreasing by -53.63% on average per year.
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-133.33%
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Revenue growth Q2Q600%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AGE. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGEX THERAPEUTICS INC
NYSEARCA:AGE (3/26/2024, 8:04:03 PM)
11.1
-1.5 (-11.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap421.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.07% | ||
| ROE | -166.86% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.36 | ||
| Quick Ratio | 0.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y